The FDA database shows a supplement, dated 14 October 2026, to an approved abbreviated new drug application for daptomycin held by Fresenius Kabi USA. The notice does not state the content of the supplement; such filings commonly cover manufacturing, labelling or packaging changes to an already approved generic.
No new indication or safety finding is implied. The CDSCO position on any equivalent change is not known from this record.
- No change to daptomycin prescribing follows from this notice.
- Generic supplements usually concern manufacturing or labelling, not efficacy.
- Check local formulary communications if your hospital stocks this supplier's product.
Why it matters
Supply and labelling of a key anti-MRSA drug is worth tracking, even when routine.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free